Codiak’s Novel Engineered Exosome Therapeutic Candidate (ExoIL-12) Being Investigated in Phase 1 Clinical Trial As Single Agent for Treatment of Early-Stage Cutaneous T Cell Lymphoma (CTCL) and, Potentially, Other Cancers

On December 21, 2020, Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the December 21, 2020 online publication of a new manuscript, “Exosome Surface Display of IL-12 Results In Tumor-Retained Pharmacology With Superior Potency and Limited Systemic Exposure Compared to Recombinant IL-12,” in Molecular Cancer Therapeutics (, a journal of the American Association for Cancer Research. exoIL-12 is a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1 clinical trial as a single agent for the treatment of early-stage cutaneous T cell lymphoma (CTCL) and potentially other cancers. This publication details the findings from the preclinical development program and highlights the potential of exoIL-12 to inhibit tumor growth by facilitating potent local pharmacology, precisely quantified doses, undetectable systemic exposure, and the robust generation of systemic anti-tumor immunity superior to that of recombinant IL-12 (rIL-12).“We believe exoIL-12 represents a potentially first-in-class approach for a number of cancers that have previously shown clinical responses to IL-12, a potent anti-tumor cytokine for which prior development has been limited due to unwanted systemic exposure and related toxicity,” said Sriram Sathyanarayanan, PhD, Senior Vice President, Preclinical Research, Codiak.
Login Or Register To Read Full Story